DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...
QOL research findings in schizophrenia are discussed and future directions suggested. Continued refinement of QOL measures to accurately assess meaningful variables in subjective life satisfaction ...
Other studies in 2024 deepened understanding of the impacts of BrainHQ training across some previously studied health conditions, including: stroke, TBI, Chemobrain, HAND, heart disease, Type 2 ...
The life expectancy of people living with schizophrenia is reduced by 10-20 years compared to the general population. Schizophrenia affects nearly 24 million people worldwide and is most commonly ...